Ceramide-Protein Interactions Modulate Ceramide-Associated Lipotoxic Cardiomyopathy

Area of Science:

• Cardiovascular Biology
• Metabolic Disorders
• Molecular Cardiology

Background:

• Lipotoxic cardiomyopathy (LCM) involves abnormal lipid accumulation in the heart, notably ceramide.
• The precise role of ceramide in the development of LCM remains incompletely understood.
• Investigating ceramide metabolism and interacting proteins is crucial for understanding LCM pathogenesis.

Purpose of the Study:

• To investigate the association between ceramide metabolism, ceramide-interacting proteins (CIPs), and lipotoxic cardiomyopathy (LCM).
• To establish a direct model of ceramide-associated LCM using the Drosophila heart.
• To identify conserved molecular mechanisms underlying ceramide-induced cardiotoxicity.

Main Methods:

• Utilized the Drosophila heart as a model organism to study ceramide-induced cardiac dysfunction.
• Administered ceramide or employed genetic manipulations to elevate ceramide levels in the fly heart.
• Identified and manipulated cardiac-specific ceramide-interacting proteins (CIPs), including Annexin-X, Unc-45, and FASN1.

Main Results:

• Ceramide feeding or elevated ceramide levels induced cardiac dilation and impaired contractility in Drosophila.
• Inhibition of ceramide synthesis effectively prevented ceramide-associated LCM, validating the model.
• Cardiac-specific manipulation of identified CIPs (Annexin-X, Unc-45, FASN1) ameliorated LCM.

Conclusions:

• Elevated ceramide levels directly contribute to lipotoxic cardiomyopathy.
• Ceramide-associated cardiotoxicity is mediated by alterations in caspase activation, sarcomeric maintenance, and lipogenesis.
• These findings highlight conserved mechanisms of LCM pathogenesis across species.